SPP1 and myeloid sarcoma: We previously showed that a substantial proportion of MS lesional T cells leaves the PVS and enters the brain parenchyma in MS, where inhibitory receptors on these cells may encounter their ligands, such as PD-L18 and, as discussed above, possibly also OPN.